H.C. Wainwright raised the firm’s price target on Perspective Therapeutics (CATX) to $12 from $10 and keeps a Buy rating on the shares. The firm says Sanofi’s deprioritization of Alphamedix eliminates a competitor for Perspective .
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CATX:
- Perspective Therapeutics Highlights Progress in Radioligand Oncology Pipeline
- Undervalued Radiopharma Pipeline and Manufacturing Platform Underpin Buy Rating and $18 Target
- Perspective Therapeutics outlines 2026 clinical and manufacturing priorities
- Perspective Therapeutics provides business updates, strategic priorities
- Perspective Therapeutics Reports Positive Interim Neuroendocrine Tumor Data